Identity
- Security key
- 12129
- Ticker
- AVTX
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2015-11-13
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- AVTX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $1,048,466,284.95
- Shares outstanding (class)
- 53,629,989
- Shares outstanding (weighted)
- 53,629,989
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 33
- Location
- WAYNE, PA
- Homepage
- https://www.avalotx.com
- Description
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.